Status:
COMPLETED
Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)
Lead Sponsor:
Seoul National University Hospital
Conditions:
Hepatic Fibrosis
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to determine: * The efficacy of MRE score as a predictor of HCC recurrence within 2 years after RFA treatment * The efficacy of each indicator (MRE score, non-invasive se...
Detailed Description
To evaluate whether MRE score reflecting hepatic fibrosis can predict the recurrence of HCC within 2 years after RFA treatment * Local recurrence/intrahepatic distant recurrence * Multivariable analy...
Eligibility Criteria
Inclusion
- Diagnosed as single hypervascular hepatocellular carcinoma initially
- AJCC stage I HCC
- Child-Pugh class A
- Planning radiofrequency ablation for HCC
- Voluntary agreement for this study
Exclusion
- Decreased kidney function (GFR \< 70 mL/min/kg)
- Contraindication to MRI (pacemaker, defibrillator)
- Contrast media hypersensitivity
- Other primary malignancy
- Acute viral hepatitis
- Prior history of liver transplantation
- Thrombosis in splenic vein or portal vein
- Patients who were enrolled to other clinical trials within 4 weeks
- Other severe chronic disease or psychiatric disease
- Pregnant or milk-feeding women
- Patients with coagulopathy, high risk of bleeding for the liver biopsy
- Patients who disagree to participate in this study
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT01447667
Start Date
October 1 2011
End Date
December 1 2022
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea